This study was done to obtain direct in vitro evidence for the possible existence of more than one type of dopaminergic binding site in homogenates of the caudate nucleus from calf brain. Five 
There are several fundamental issues as yet unresolved concerning the nature of the dopaminergic receptor sites in the brain. A major question is whether or not there exists more than one type of dopamine receptor in the brain. Compelling evidence from in vio studies (1) (2) (3) (4) (5) points to the existence of presynaptic receptors (or autoreceptors) in addition to the classical type of postsynaptic receptor. Cools et al. have even further subdivided (from in vivo data) the pre-and postsynaptic receptors into excitatory and inhibitory classes (6) .
There has not been, however, any direct evidence for such multiple brain dopamine receptors from direct radioreceptor studies in vitro (7) . Hitherto, only a single high-affinity site has been described for such dopamine receptor 3H-labeled ligands as [3H] dopamine (8) (9) (10) (11) (12) (13) (14) , [3H]haloperidol (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , [3H]apomorphine (17) , and [3H]spiperone (18, 19) . Recently, however, using [3H]dihydroergocryptine to tag dopamine receptors (in the presence of excess phentolamine to preclude binding to a-adrenergic sites), we obtained direct evidence for two dopaminergic binding sites (20) . Encouraged by these observations with [3H]dihydroergocryptine, we reexamined in detail the binding patterns of the other four dopaminergic 3H-labeled ligands and found the same type of evidence for at least two high-affinity dopaminergic binding sites in each case.
MATERIALS AND METHODS
Preparation of Calf Caudate Nucleus Homogenates. The experiments were done on crude homogenates of calf caudate nucleus, prepared as previously described (16) . In order to retain all the dopamine receptors, the homogenates were not purified or subfractionated. Calf brains were obtained fresh from the Canada Packers Hunnisett plant (Toronto). The caudates were removed within 2 hr after death, pooled, sliced into small cubes, and suspended in buffer at an approximate concentration of 50 mg of wet weight per ml of buffer. The buffer contained 15 mM Tris-HCI (pH 7.4), 5 mM Na2EDTA, 1.1 mM ascorbate, and 12.5 ,uM nialamide. A preliminary crude homogenate of the suspension was made using a glass homogenizer with a Teflon piston (0. 12-0.18 mm clearance). This piston, rotating
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at 500 rpm, was passed up and down 20 times. The crude homogenate was incubated at 370 for 60 min and then stored in 3-ml aliquots at -200. Before using, the samples were thawed, resuspended in the glass-Teflon homogenizer (10 up-and-down passes) by hand, and centrifuged at 39,000 X g for 15 min at 40; the supernatant was discarded and the pellet was resuspended in 10 ml of buffer. The suspension was finally homogenized by a Polytron homogenizer (Brinkmann Instruments) at a setting of 7 (full range = 10) for 20 sec, using a PT-10 homogenizer probe and a 50-ml polycarbonate tube to contain the suspension. Homogenization at settings higher than 7 led to a loss of protein through the glass-fiber GF/B filters used in the radioreceptor assays. Except where indicated, the homogenates were always kept chilled on ice.
[3H]Apomorphine Binding Assays. The [3H]apomorphine had been custom-prepared for this laboratory by New England Nuclear Corp., Boston, and used without further purification; the specific activity was 14.1 Ci/mmol (in 1975). The material was stored in ethanol at -20°. The [3H]apomorphine binding assays were done using 12-X 75-mm glass test tubes in which the following aliquots were placed (using Eppendorf Brinkmann pipettes with polypropylene tips): 0.2 ml of [3H]apomorphine (final concentration of 0.7 nM); 0.2 ml of brain homogenate (always added last, and containing between 0.2-and 0.3 mg of protein); 0.1 ml of drug solution; and 0.1 ml of a second drug solution or buffer. Each determination was always done in sextuplicate. After the sample was incubated for 30 min (220), an aliquot of 0.5 ml was removed (polypropylene pipette tip) from the mixture and filtered under reduced pressure through a glass-fiber filter (GF/B, Whatman, 24-mm diameter) using a Millipore stainless steel mesh support for the filter; the filtration took less than 1 sec. The filter was then washed twice with 7.5 ml of buffer per wash. The wash buffer was delivered by gravity from a syringe Re-pipette over a period of 4 sec. The filters were not blotted or dried but were placed directly into liquid scintillation vials; 8 ml of Aquasol (New England Nuclear) was added and the samples were monitored for 3H after they were stored at 40 for at least 6 hr to allow temperature equilibration and to permit the glass-fiber filters to become uniformly translucent.
Specific binding of [3H]apomorphine was defined as the total amount of [3H]apomorphine bound minus that amount of [3H]apomorphine bound in the presence of 500 nM nonradioactive apomorphine, in accordance with previous work (16, 17) . The exact protein concentration in each homogenate was measured and the amount of [3H]apomorphine specifically bound was expressed in terms of fmol of [3H]apomorphine bound per mg of homogenate protein.
The binding assays described below were performed in the same manner except for the differences specified.
[3H]Dopamine Binding Assays. The [3H]dopamine was purchased from New England Nuclear, and the specific activity was 8.95 Ci/mmol. The material was stored at -200 in 0.02% Proc. Nati. Acad. Sci. USA 75 (1978) The wash volume was 5 ml. Specific binding was defined as the total amount of radioactivity bound minus that bound in the presence of 500 nM nonradioactive dopamine (9) .
[3HjDihydroergocryptine Binding Assays (20) (21) (22) in a biphasic manner (Fig. 3) (Fig. 5) . Although the inhibition of [3H]spiroperidol by dopamine was not significantly different from a monophasic pattern, there were clearly two distinct inhibitory phases for the action of (-)-norepinephrine on this 3H-labeled ligand (Fig. 5) .
We tested whether it was possible to block selectively one set of sites. We chose [3H]dihydroergocryptine for this purpose, because there was a clear demarcation at 10 1M norepinephrine (Fig. 3) between the two sets of sites. We tested whether the apparent affinity of a potent neuroleptic (spiroperidol) for competition with [3H]dihydroergocryptine could be shifted to a higher affinity by blocking one set of sites with 10 ,M norepinephrine. In fact, this was observed (Fig. 6) In other words, the inhibitory slopes for agonists and antagonists on the binding of 3H-labeled agonists and 3H-labeled antagonists were never parallel. The present results cannot be explained by models based on negative cooperativity as proposed by Snyder and his coworkers (12) , because there would be no biphasic behavior in such a displacement curve. These results can be explained by at least two models: (a) Two high-affinity sites for which the 3H-labeled ligand and the potent competing agents have similar affinities, but for which the low-affinity agents have significantly different affinities. (b) Induction of increased binding sites by the high concentration of agents used in the competition experiments with low-affinity competing ligands. This effect could result in shallow competition curves or biphasic curves, depending upon the extent of the induction of binding sites. Induction of binding sites in vitro has been detected in this laboratory (23) .
Further work must be directed at testing these hypotheses for the biphasic and shallow competition curves.
